Redeye provides a research update following the Q4 report recently published by Isofol. The report came in largely in line with our estimates, with only a slightly lower OPEX than anticipated. With a bolstered cash position through the oversubscribed rights issue and a successfully completed second dose level in the phase Ib/II study, we continue to have a positive outlook on the company.
LÄS MER
